Clinicians should consider trastuzumab deruxtecan (T-Dxd) as a viable treatment option for inoperable or metastatic low HER2 breast cancer, especially in patients who have received one or two prior lines of chemotherapy. This evidence concerns the gene ERBB2 and breast cancer.